Nanexa publishes annual report for 2024

MARKN.

Nanexa AB (publ) today announces that the annual report for 2024 has been published and is available on the company's website https://nanexa.com/en/financial-reports.

” We have taken major steps during 2024 in the development of our scale formulation for one-month depots.”

“We started 2024 with a strategy focused on three areas. The NEX-22 project, the collaboration with Novo Nordisk and the implementation of a few prioritised partner projects. That strategy has been successful in many ways and we are ending the year strongly. We are proud to have created what we consider to be the first depot formulation of a GLP-1 agonist with month-long release demonstrated in a clinical study. At the same time, the collaboration with our most important partners is progressing well”, says David Westberg, CEO of Nanexa.

Datum 2025-04-10, kl 09:40
Källa MFN
Bifogade filer
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.
Cashback är begränsad till högst $100. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.